Risk factors for cancer in renal transplant recipients

被引:105
作者
Danpanich, E [1 ]
Kasiske, BL [1 ]
机构
[1] Hennepin Cty Med Ctr, Dept Med, Div Nephrol, Minneapolis, MN 55415 USA
关键词
D O I
10.1097/00007890-199912270-00008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background, Cancer continues to be an important cause of morbidity and mortality after renal transplantation. Unfortunately, risk factors for cancer have not been well defined. Methods. We examined risk factors for invasive, life-threatening malignancies among 1500 renal transplant recipients. Both univariate and multivariate Cox proportional hazards analyses were used. Results. There were 87 tumors in 88 patients. Actuarial survival free of cancer was 95.9% at 5 years, 92.3% at 10 years, 86.6% at 15 years, and 82.6% at 20 years. Among multiple possible risk factors, the adjusted, relative risk attributable to age at transplantation (compared to age <45 years) was 2.00 (95% confidence interval: 1.21-3.30, P=0.007) for age greater than or equal to 45 and <60 years (29.1%, of total were in this age range), and 3.81 (95% confidence interval: 2.05-7.06, P<0.001) for age greater than or equal to 60 years (11.6%). The relative risk attributable to pretransplant splenectomy (47.8%, now large abandoned) was 1.87 (95% confidence interval: 1.12-3.12, P=0.016). Patients with renal disease from type 1 diabetes had a lower risk of cancer, 0.19 (95% confidence interval: 0.05-0.08, P=0.015). A history of invasive cancer pretransplant (2.5%) increased the risk, of posttransplant cancer to 2.38 (95% confidence interval: 1.18-4.83, P=0.015). Cigarette smoking was also associated with an increased risk, with each 10 pack-years smoked at transplant increasing the risk of cancer by 1.12 (1.02-1.21, P=0.016). The era when transplantation occurred, the type of prophylactic immunosuppression used, the occurrence of acute rejection, or its treatment did not alter the risk of cancer. Conclusions. The risk of cancer continues to increase 15-20 years after transplantation. The identification of splenectomy as a new risk factor, even several years after this immunosuppression strategy has been abandoned, demonstrates that the risk of immunosuppression may take years to become manifest. Efforts to reduce immunosuppression, particularly for patients greater than or equal to 45 years of age at transplant, along with a greater effort to discourage cigarette smoking, may help reduce the risk of cancer after renal transplantation.
引用
收藏
页码:1859 / 1864
页数:6
相关论文
共 30 条
[1]   Malignancies in patients under long-term immunosuppression after kidney transplantation [J].
Behrend, M ;
Kolditz, M ;
Kliem, V ;
Oldhafer, KJ ;
Brunkhorst, R ;
Frei, U ;
Pichlmayr, R .
TRANSPLANTATION PROCEEDINGS, 1997, 29 (1-2) :834-835
[2]   MALIGNANCIES AFTER RENAL-TRANSPLANTATION - THE EDTA-ERA REGISTRY EXPERIENCE [J].
BRUNNER, FP ;
LANDAIS, P ;
SELWOOD, NH .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1995, 10 :74-80
[3]   Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens [J].
Dantal, J ;
Hourmant, M ;
Cantarovich, D ;
Giral, M ;
Blancho, G ;
Dreno, B ;
Soulillou, JP .
LANCET, 1998, 351 (9103) :623-628
[4]   DEVELOPMENT OF CHRONIC LYMPHOCYTIC-LEUKEMIA AFTER POSTTRAUMATIC SPLENECTOMY [J].
DEMETER, J ;
PALOCZI, K ;
VARGHA, P ;
LEHOCZKY, D .
BLUT, 1990, 60 (06) :331-333
[5]   The Agency for Health Care Policy and Research Smoking Cessation Clinical Practice Guideline [J].
Fiore, MC ;
Wetter, DW ;
Bailey, WC ;
Bennett, G ;
Cohen, SJ ;
Dorfman, SF ;
Goldstein, MG ;
Gritz, ER ;
Hasselblad, V ;
Henningfield, JE ;
Heyman, RB ;
Holbrook, J ;
Husten, C ;
Jaen, CR ;
Kohler, C ;
Kottke, TE ;
Lando, HA ;
Manley, M ;
Mecklenburg, R ;
Melvin, C ;
Mullen, PD ;
Nett, LM ;
Piasecki, TM ;
Robinson, L ;
Rothstein, D ;
Schriger, DL ;
Stitzer, ML ;
Stachenko, S ;
Tommasello, A ;
Villejo, L ;
Wewers, ME ;
Baker, TB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (16) :1270-1280
[6]   Malignancy after renal transplantation: Analysis of incidence and risk factors in 1700 patients followed during a 25-year period [J].
Hiesse, C ;
Rieu, P ;
Kriaa, F ;
Larue, JR ;
Goupy, C ;
Neyrat, N ;
Charpentier, B .
TRANSPLANTATION PROCEEDINGS, 1997, 29 (1-2) :831-833
[7]  
Hoshida Y, 1997, INT J CANCER, V71, P517, DOI 10.1002/(SICI)1097-0215(19970516)71:4<517::AID-IJC3>3.0.CO
[8]  
2-X
[9]  
Hughes JR, 1996, AM J PSYCHIAT, V153, P1
[10]   TRIPLE THERAPY AND INCIDENCE OF DE-NOVO CANCER IN RENAL-TRANSPLANT RECIPIENTS [J].
KEHINDE, EO ;
PETERMANN, A ;
MORGAN, JD ;
BUTT, ZA ;
DONNELLY, PK ;
VEITCH, PS ;
BELL, PRF .
BRITISH JOURNAL OF SURGERY, 1994, 81 (07) :985-986